FIELD: biotechnology; medicine.
SUBSTANCE: group of inventions refers to pyrrolobenzodiazepine antibody-drug conjugates and use thereof. Disclosed is a conjugate of formula I:
,
where L is an antibody or its antigen-binding fragment to a tumor-associated antigen, DL is a link of formula II:
,
where either R10 and R11 form a double nitrogen-carbon bond between the nitrogen and carbon atoms with which they are bonded, or R11 is OH and R10 is:
,
p = 1–20.
EFFECT: said conjugates can be used for treating a proliferative disease; conjugates are well tolerated in toxicity studies in various animal species, which provides a high therapeutic index of such conjugates.
20 cl, 4 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| PEPTIDOMIMETIC COMPOUNDS AND THEIR CONJUGATES OF ANTIBODIES WITH DRUGS | 2014 |
|
RU2689388C1 |
| LC-MS/MS METHOD FOR MULTIPLE REACTIONS MONITORING TO IDENTIFY THERAPEUTIC ANTIBODIES IN ANIMAL SPECIES USING FRAMEWORK SIGNATURE PEPTIDES | 2012 |
|
RU2638806C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUITIONS AND THEIR CONJUGATES PRODUCED BY GENE ENGINEERING | 2011 |
|
RU2626537C2 |
| RADIOACTIVE ZIRCONIUM- LABELLED ENGINEERED CYSTEINE ANTIBODIES CONJUGATES | 2010 |
|
RU2562862C2 |
| NOVEL ANTIBODY CONJUGATES AND USES THEREOF | 2014 |
|
RU2684468C2 |
| BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | 2014 |
|
RU2693438C2 |
| ANTIBODIES AGAINST TEICHOIC ACID CONJUGATE AND THEIR CONJUGATES | 2014 |
|
RU2687044C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| MOLECULE CONTAINING spr0096 AND spr2021 | 2012 |
|
RU2636350C2 |
